LeishGen: Advancing in the Detection of Genetic Resistance Biomarkers in Leishmania infantum

Did you know the number of canine leishmaniasis (CanL) cases recorded in the Mediterranean basin each year? One key challenge in treating this disease is the parasite's drug resistance. Leishmania infantum, despite its complex genome, offers us the opportunity to understand the genetic predisposition to resistance against current treatments.

On April 19th and 20th, we had the privilege of participating in the prestigious ALIVE2 congress (Animal Leishmaniosis International Veterinary Event) in Nice, organized by LeishVet. This event, a cornerstone in the field of leishmaniasis research, provided an invaluable platform for us to immerse ourselves in a collaborative environment and share experiences with esteemed veterinarians, researchers, and pharmaceutical and medical industry leaders. We established a robust multidisciplinary network of collaborators, reflecting the significance of this event in advancing our research on Leishmania.

During the congress, we shared Nano1Health's innovations in optimizing the treatment of this disease with experts in leishmaniasis. Marina Carrasco presented our diagnostic platforms, LeishGenApp and LeishGenR. These platforms, developed over two years along the Neotec project with the support of the CDTI, are designed to detect resistance to standard treatments in Leishmania infantum.

LeishGenApp is a user-friendly application that utilizes genome sequencing, advanced bioinformatics algorithms and data visualization techniques to identify genetic resistance biomarkers in Leishmania infantum from cultured samples, providing comprehensive reports. LeishGenR, on the other hand, is a robust research tool that allows for the direct analysis of clinical samples.

We are thrilled to share the news that Marina's groundbreaking presentation, titled "Drug- resistance Biomarkers in Leishmania infantum through Nanopore Sequencing and Structural Variants Analysis," was not only well-received but also recognized as the Best Oral Communication in the field of research. This achievement is a testament to the significant strides we are making in understanding and combating leishmaniasis. Congratulations, Marina, on this well-deserved recognition!

If you want to learn more about our research and how we can answer these questions, please contact us at info@nano1health.com or our website at www.nano1health.com.